Tone – CJC 1295 Without DAC (5mg) + Ipamorelin (5mg)

Description

OVERVIEW

This peptide blend contains CJC-1295 (5mg) and Ipamorelin (5mg), totaling 10mg, and is designed to synergistically enhance growth hormone (GH) secretion through two distinct mechanisms:

• CJC-1295 activates growth hormone-releasing hormone (GHRH) receptors, stimulating natural pulsatile GH production.
• Ipamorelin functions as a selective GH secretagogue, mimicking ghrelin while suppressing cortisol and prolactin spikes.

Together, these peptides contribute to:

• Muscle growth and enhanced recovery
• Fat loss and metabolic optimization
• Improved bone density and joint healing
• Cognitive support and neuroprotection

This combination is widely researched for its potential anti-aging, muscle-building, and metabolic-enhancing effects.

RESEARCH

How CJC-1295 and Ipamorelin Work Together

Both peptides increase growth hormone levels, but they do so through different biological pathways:

• CJC-1295 binds to GHRH receptors, triggering sustained GH release in a natural pulsatile cycle.
• Ipamorelin stimulates the GH secretagogue receptor (GHSR-1a), mimicking ghrelin’s effects while avoiding excessive cortisol and prolactin elevation.

By combining these mechanisms, the peptides enhance growth hormone signaling while maintaining the body’s natural GH pulse rhythm.

Effects on Muscle Growth and Fat Reduction

Research indicates that CJC-1295 and Ipamorelin may contribute to:

• Increased protein synthesis, promoting muscle hypertrophy and faster recovery.
• Enhanced fat metabolism, reducing both visceral and subcutaneous fat.
• Improved insulin sensitivity, optimizing glucose uptake and metabolic function.

Bone Health and Joint Repair

Studies suggest that this peptide combination supports bone strength and joint health by:

• Stimulating osteoblast activity, enhancing bone formation.
• Reducing inflammation, accelerating cartilage and tissue repair.

These findings indicate potential applications for osteoporosis, injury recovery, and joint degeneration.

Cognitive Benefits and Anti-Aging Potential

Emerging research suggests that growth hormone-releasing peptides (GHRPs) may have neuroprotective effects, potentially supporting brain health and longevity. Key benefits may include:

• Enhanced neurogenesis, leading to the formation of new neurons.
• Protection against oxidative stress, safeguarding brain cells from age-related decline.
• Improved memory and cognitive processing speed.

This suggests that CJC-1295 and Ipamorelin could play a role in healthy aging and cognitive function maintenance.

STRUCTURE

CJC-1295

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3367.954 g/mol
• CAS Registry Number: 446262-90-4

Ipamorelin

• Molecular Formula: C₃₈H₄₉N₉O₅
• Molecular Weight: 711.868 g/mol
• CAS Registry Number: 170851-70-4

CITATIONS

1. Raun, K. et al. Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol. (1998).
2. Andersen, N. B. et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm. IGF Res. (2001).
3. Svensson, J. et al. The GH secretagogues ipamorelin and GHRP-6 increase bone mineral content in adult female rats. J. Endocrinol. (2000).
4. Adeghate, E. & Ponery, A. S. Mechanism of ipamorelin-evoked insulin release from the pancreas. Neuro Endocrinol. Lett. (2004).
5. Beck, D. E. et al. Proof-of-concept study of ipamorelin for postoperative ileus management. Int. J. Colorectal Dis. (2014).
6. Greenwood-Van Meerveld, B. et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility. J. Exp. Pharmacol. (2012).
7. Alba, M. et al. Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in knockout mice. Am. J. Physiol. Endocrinol. Metab. (2006).
8. Ionescu, M. & Frohman, L. A. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J. Clin. Endocrinol. Metab. (2006).
9. Van Hout, M. C. & Hearne, E. Netnography of female use of the synthetic growth hormone CJC-1295. Subst. Use Misuse. (2016).
10. Jetté, L. et al. hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats.Research Gate.